射血分数降低的心力衰竭合并心房颤动患者口服抗凝药使用不足的原因与后果
出血风险(HAS-BLED)而非卒中风险(CHA2DS2-VASc)主导了抗凝决策,OAC未使用与不良结局相关。
要点
- 合并心衰与房颤患者中仅58%接受口服抗凝药,使用不足普遍存在
- HAS-BLED每增加1分,OAC使用OR为0.32,出血风险过度影响决策
- CHA2DS2-VASc每增加1分,OAC使用OR为1.24,卒中风险驱动作用不足
核心结论
- 合并心衰的房颤患者未接受口服抗凝药并非基于合理依据,出血风险对决策的不当影响超过卒中风险。
主要发现
- CHA2DS2-VASc每增加1分,OAC使用OR为1.24(95%CI 1.21-1.27),死亡/卒中HR为1.08(95%CI 1.06-1.10)。
- HAS-BLED每增加1分,OAC使用OR为0.32(95%CI 0.30-0.33),死亡/大出血HR为1.18(95%CI 1.15-1.21)。
- 高vs低CHA2DS2-VASc的OAC使用OR为1.23(95%CI 1.15-1.32),死亡/卒中HR为1.25(95%CI 1.19-1.30)。
- 高vs低HAS-BLED的OAC使用OR为0.20(95%CI 0.19-0.21),死亡/大出血HR为1.28(95%CI 1.21-1.34)。
临床怎么用
- 对合并心衰的房颤患者应基于卒中风险积极启用口服抗凝药,避免因出血风险而过度停用。
- 出血风险评分高不应成为拒绝抗凝的唯一理由,需综合评估卒中与出血风险后个体化决策。
局限性
- 研究为回顾性登记分析,可能存在未测量混杂因素。
- 高与低CHA2DS2-VASc及HAS-BLED评分以中位数定义,具体阈值未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Atrial fibrillation (AF) is common in patients with heart failure (HF), and oral anticoagulants (OAC) are indicated. The aim was to assess prevalence of, predictors of and consequences of OAC non-use. METHODS: We included patients with AF, HF and no previous valve replacement from the Swedish Heart Failure Registry. High and low CHA2DS2-VASc and HAS-BLED scores were defined as above/below median. Multivariable logistic regressions were used to assess the associations between baseline characteristics and OAC use and between CHA2DS2-VASc and HAS-BLED scores and OAC use. Multivariable Cox regressions were used to assess associations between CHA2DS2-VASc and HAS-BLED scores, OAC use and two composite outcomes: all-cause death/stroke and all-cause death/major bleeding. RESULTS: Of 21 865 patients, only 12 659 (58%) received OAC. Selected predictors of OAC non-use were treatment with platelet inhibitors, less use of HF treatments, paroxysmal AF, history of bleeding, no previous stroke, planned follow-up in primary care, older age, living alone, lower income and variables associated with more severe HF. For each 1-unit increase in CHA2DS2-VASc and HAS-BLED, the ORs (95% CI) of OAC use were 1.24 (1.21-1.27) and 0.32 (0.30-0.33), and the HRs for death/stroke were 1.08 (1.06-1.10) and for death/major bleeding 1.18 (1.15-1.21), respectively. For high versus low CHA2DS2-VASc and HAS-BLED, the ORs of OAC use were 1.23 (1.15-1.32) and 0.20 (0.19-0.21), and the HRs for death/stroke were 1.25 (1.19-1.30) and for death/major bleeding 1.28 (1.21-1.34), respectively. CONCLUSIONS: Patients with AF and concomitant HF do not receive OAC on rational grounds. Bleeding risk inappropriately affects decision-making more than stroke risk.
引用
- Savarese G, Sartipy U, Friberg L, et al. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. Heart. 2018. PMID: 29371374. doi:10.1136/heartjnl-2017-312720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。